Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

Thursday’s Trading Day
11.62 +0.83 / +7.69%
As of Aug 27
Day’s Change
Friday’s Pre-Market   Switch to standard view »
11.24 -0.38 / -3.27%
 
Volume: 2.8K
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.1B

Company Description

Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in development of novel recombinant vaccines to address a broad range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles and recombinant nanoparticle vaccines. Its product pipeline targets a variety of infectious diseases and currently has completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and Respiratory Syncytial Virus. Novavax was founded in 1987 and is headquartered in Gaithersburg, MD.

Contact Information

Novavax, Inc.
20 Firstfield Road
Gaithersburg Maryland 20878
P:(240) 268-2000
Investor Relations:

Employees

Shareholders

Individual stakeholders7.34%
Mutual fund holders48.32%
Other institutional20.41%

Top Executives

Stanley C. ErckPresident, Chief Executive Officer & Director
Barclay A. PhillipsChief Financial Officer, Treasurer & Senior VP
Gregory M. GlennSenior Vice President-Research & Development
Louis F. FriesChief Medical Officer & Vice President
John A. HerrmannSecretary, Senior Vice President & General Counsel